Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Enrico Mihich, MD: In Memoriam (1928-2016).

Foti M, Rustum YM.

Cancer Res. 2017 Jul 1;77(13):3383-3385. doi: 10.1158/0008-5472.CAN-17-1723. No abstract available.

PMID:
28674202
2.

Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.

Tóth K, Chintala S, Rustum YM.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):642-7. doi: 10.1097/PAI.0000000000000012.

3.

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.

Cao S, Durrani FA, Tóth K, Rustum YM.

Br J Cancer. 2014 Apr 2;110(7):1733-43. doi: 10.1038/bjc.2014.85. Epub 2014 Mar 11.

4.

MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice.

Padi SK, Zhang Q, Rustum YM, Morrison C, Guo B.

Gastroenterology. 2013 Aug;145(2):437-46. doi: 10.1053/j.gastro.2013.04.012. Epub 2013 Apr 22.

5.

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F.

PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571. Epub 2012 Sep 19.

6.
7.

In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges.

Kasturirangan V, Nair BM, Kariapper MT, Lesniak WG, Tan W, Bizimungu R, Kanter P, Toth K, Buitrago S, Rustum YM, Hutson A, Balogh LP, Khan MK.

Nanotoxicology. 2013 Jun;7(4):441-51. doi: 10.3109/17435390.2012.668570. Epub 2012 Mar 20.

PMID:
22394369
8.

Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.

Hu Y, Spengler ML, Kuropatwinski KK, Comas-Soberats M, Jackson M, Chernov MV, Gleiberman AS, Fedtsova N, Rustum YM, Gudkov AV, Antoch MP.

Oncotarget. 2011 Dec;2(12):1279-90.

9.

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

Cao S, Durrani FA, Rustum YM, Yu YE.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1107-11. doi: 10.1007/s00280-011-1820-8. Epub 2012 Jan 12.

10.

Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.

Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6.

11.

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M.

Oral Oncol. 2011 Jun;47(6):459-66. doi: 10.1016/j.oraloncology.2011.04.001. Epub 2011 May 6.

12.

Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.

Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, Hoffman RM, Seshadri M.

Anticancer Res. 2011 Feb;31(2):387-93.

13.

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

Saifo MS, Rempinski DR Jr, Rustum YM, Azrak RG.

Mol Cancer. 2010 Dec 2;9:310. doi: 10.1186/1476-4598-9-310.

14.

Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

Chintala S, Tóth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM.

Chemotherapy. 2010;56(3):223-33. doi: 10.1159/000316334. Epub 2010 Jun 11.

15.

Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

Rustum YM, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A.

J Oncol. 2010;2010:396286. doi: 10.1155/2010/396286. Epub 2010 Apr 27.

16.

Double immunohistochemical staining method for HIF-1alpha and its regulators PHD2 and PHD3 in formalin-fixed paraffin-embedded tissues.

Vaughan MM, Toth K, Chintala S, Rustum YM.

Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):375-81. doi: 10.1097/PAI.0b013e3181d6bd59.

17.

Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers.

Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, Johnson CS, Rustum YM, Porter CW.

Am J Pathol. 2010 Apr;176(4):1629-38. doi: 10.2353/ajpath.2010.090414. Epub 2010 Feb 4.

18.

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.

Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. doi: 10.1007/s00280-009-1238-8. Epub 2010 Jan 12.

19.

Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

Bhattacharya A, Tóth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM.

Clin Colorectal Cancer. 2009 Jul;8(3):155-62. doi: 10.3816/CCC.2009.n.025.

20.

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ.

Clin Cancer Res. 2009 May 1;15(9):3189-95. doi: 10.1158/1078-0432.CCR-08-2999. Epub 2009 Apr 21.

21.

Does celecoxib have a role in the treatment of patients with colorectal cancer?

Fakih MG, Rustum YM.

Clin Colorectal Cancer. 2009 Jan;8(1):11-4. doi: 10.3816/CCC.2009.n.002. Review.

PMID:
19203891
22.

Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells.

Azrak RG, Frank CL, Ghadersohi A, Rustum YM.

Cancer Biol Ther. 2008 Dec;7(12):1901-8. Epub 2008 Dec 7.

PMID:
18981709
24.

Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.

Ramnath N, Yu J, Khushalani NI, Gottlieb RH, Schwarz JK, Iyer RV, Rustum YM, Creaven PJ.

Anticancer Drugs. 2008 Aug;19(7):749-52. doi: 10.1097/CAD.0b013e328301c54f.

PMID:
18594219
25.

Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.

Fakih MG, Bullarddunn K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum YM, Ross ME, Levea C, Puthillath A, Park YM, Rajput A.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):650-7. doi: 10.1016/j.ijrobp.2008.01.020. Epub 2008 Jun 17.

PMID:
18565686
26.

Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.

Bhattacharya A, Seshadri M, Oven SD, Tóth K, Vaughan MM, Rustum YM.

Clin Cancer Res. 2008 Jun 15;14(12):3926-32. doi: 10.1158/1078-0432.CCR-08-0212.

27.

A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.

Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):499-508. Epub 2007 Nov 8.

PMID:
17989978
28.

Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.

Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM.

Clin Cancer Res. 2007 Feb 1;13(3):965-71.

29.

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF Jr, Prey J, Smith PF, Rustum YM.

Biochem Pharmacol. 2007 May 1;73(9):1280-7. Epub 2006 Dec 22.

30.

The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.

Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM.

Mol Cancer Ther. 2006 Oct;5(10):2540-8.

31.

Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.

Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, Bellnier DA.

Neoplasia. 2006 Jul;8(7):534-42.

32.

A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.

Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM.

Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1462-70. Epub 2006 Jun 5.

PMID:
16750332
34.

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM.

Clin Cancer Res. 2006 Feb 15;12(4):1237-44.

35.

High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer.

Bouvet M, Spernyak J, Katz MH, Mazurchuk RV, Takimoto S, Bernacki R, Rustum YM, Moossa AR, Hoffman RM.

Cancer Res. 2005 Nov 1;65(21):9829-33.

36.
37.

S-phase modulation by irinotecan: pilot studies in advanced solid tumors.

Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM.

Cancer Chemother Pharmacol. 2005 Nov;56(5):447-54. Epub 2005 Jun 10.

PMID:
15947933
38.

Image analysis using the fluorochromasia assay to quantify tumor drug sensitivity.

Gibbs JF, Rustum YM, Slocum HK.

Methods Mol Med. 2005;110:185-95.

PMID:
15901936
39.

Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM.

Mol Cancer Ther. 2005 May;4(5):843-54.

40.
41.

Synergistic antitumor activity of capecitabine in combination with irinotecan.

Cao S, Durrani FA, Rustum YM.

Clin Colorectal Cancer. 2005 Jan;4(5):336-43.

PMID:
15663838
42.
43.

Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.

Antony S, Kohlhagen G, Agama K, Jayaraman M, Cao S, Durrani FA, Rustum YM, Cushman M, Pommier Y.

Mol Pharmacol. 2005 Feb;67(2):523-30. Epub 2004 Nov 5.

44.

Thymidylate synthase: a critical target in cancer therapy?

Rustum YM.

Front Biosci. 2004 Sep 1;9:2467-73. Review.

PMID:
15353299
46.
47.

Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM.

Clin Cancer Res. 2004 Feb 1;10(3):1121-9.

48.

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.

Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U.

Ann Oncol. 2003 Sep;14(9):1442-8.

PMID:
12954586
50.

Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments.

Backus HH, Rustum YM, van Groeningen CJ, Peters GJ.

Clin Colorectal Cancer. 2001 Aug;1(2):121-7. Review.

PMID:
12445371

Supplemental Content

Loading ...
Support Center